AstraZeneca PLC Total Voting Rights (4358V)
01 Diciembre 2023 - 9:00AM
UK Regulatory
TIDMAZN
RNS Number : 4358V
AstraZeneca PLC
01 December 2023
1 December 2023 15:00 GMT
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1. As at 30 November 2023 the issued share capital of
AstraZeneca PLC with voting rights is 1,549,926,211 ordinary shares
of US$0.25. No shares are held in Treasury. Therefore, the total
number of voting rights in AstraZeneca PLC is 1,549,926,211.
The above figure for the total number of voting rights may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, AstraZeneca PLC
under the UK Financial Conduct Authority's Disclosure and
Transparency Rules.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFLFVFFDLLIIV
(END) Dow Jones Newswires
December 01, 2023 10:00 ET (15:00 GMT)
Astrazeneca (LSE:0A4J)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Astrazeneca (LSE:0A4J)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024